Duplex quantitative Reverse-Transcriptase PCR for simultaneous assessment of drug activity against Leishmania intracellular amastigotes and their host cells

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 4, Issue 1, 2014, Pages 14-19

  Van den Bogaart, Erika ^a   Schoone, Gerard J ^a   Adams, Emily R ^a,b   Schallig, Henk D F H ^a  

^a ROYAL TROPICAL INSTITUTE   (Netherlands)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cell viability; Drug screening; Leishmaniasis; Polymerase chain reaction

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; ANTIPROTOZOAL AGENT; BETA 2 MICROGLOBULIN; IMIPRAMINE; MILTEFOSINE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PAROMOMYCIN; RNA 18S; UNCLASSIFIED DRUG; VUF 11852; VUF 11854; VUF 11857; VUF 13577; VUF11856;

AMASTIGOTE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG MONITORING; DRUG SCREENING; HOST CELL; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PARASITE VIABILITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84889602199     PISSN: 22113207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2013.11.001     Document Type: Article

References (27)

1. Alvar J., Vélez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., den Boer M., the WHO Leishmaniasis Control Team Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7(5):e35671.
2. Ashuthos, Gupta S., Ramesh, Sundar S., Goyal N. Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob. Agents Chemother. 2005, 49:3776-3783.
3. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307-310.
4. Buckner F.S., Wilson A.J. Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. Am. J. Trop. Med. Hyg. 2005, 72(5):600-605.
5. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19(1):111-126.
6. Croft S.L., Seifert K., Yardley V. Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 2006, 123(3):399-410.
7. Dorlo T.P.C., Van Thiel P.P., Schoone G.J., Stienstrsa Y., van Vugt M., Beijnen J.H., de Vries P.J. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Negl. Trop. Dis. 2011, 5(12):e1436.
8. Gomes L.I., Gonzaga F.M., de Morais-Teixeira E., de Souza-Lima B.S., Freire V.V., Rabello A. Validation of quantitative real-time PCR for the in vitro assessment of antileishmanial drug activity. Exp. Parasitol. 2012, 131(2):175-179.
9. Grogl M., Thomason T.N., Franke E.D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 1992, 47:117-126.
10. Gupta S., Nishi Visceral leishmaniasis: experimental models for drug discovery. Indian J. Med. Res. 2011, 133:27-39.
11. Lang T., Goyard S., Lebastard M., Milon G. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol. 2005, 7:383-392.
12. Mahoney D., Carey K., Fu M.H., Snow R., Parise G., Tarnopolsky M. Real-time RT-PCR analysis of housekeeping genes in human skeletal muscle following acute exercise. Physiol. Genomics 2004, 18(2):226-231.
13. Monzote L. Current treatment of leishmaniasis: a review. Open Antimicrob. Agents J. 2009, 1:9-19.
14. Murray P., Wynn T. Obstacles and opportunities for understanding macrophage polarization. J. Leukocyte Biol. 2011, 89(4):557-563.
15. Okuno T., Goto Y., Matsumoto Y., Otsuka H., Matsumoto Y. Applications of recombinant Leishmania amazonensis expressing EGFP and the β-galactosidase gene for drug screening and histopathological analysis. Exp. Anim. 2003, 52(2):109-118.
16. Ordóñez-Gutiérrez L., Martínez M., Rubio-Somoza I., Díaz I., Mendez S., Alunda J.M. Leishmania infantum: antiproliferative effect of recombinant plant cystatins on promastigotes and intracellular amastigotes estimated by direct counting and real-time PCR. Exp. Parasitol. 2009, 123(4):341-346.
17. Orrling K.M., Jansen C., Vu X.L., Balmer V., Bregy P., Shanmugham A., England P., Bailey D., Cos P., Maes L., Adams E., van den Bogaart E., Chatelain E., Ioset J.R., van de Stolpe A., Zorg S., Veerman J., Seebeck T., Sterk G.J., de Esch I.J., Leurs R. Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1. J. Med. Chem. 2012, 55(20):8745-8756.
18. Prina E., Roux E., Mattei D., Milon G. Leishmania DNA is rapidly degraded following parasite death: an analysis by microscopy and real-time PCR. Microbes Infect. 2007, 9:1307-1315.
19. Reimão J.Q., Colombo F.A., Pereira-Chioccola V.L., Tempone A.G. In vitro and experimental therapeutic studies of the calcium channel blocker bepridil: detection of viable Leishmania (L.) chagasi by real-time PCR. Exp. Parasitol. 2001, 128(2):111-115.
20. Romero I., Téllez J., Suárez Y., Cardona M., Figueroa R., Zelazny N. Viability and burden of Leishmania in extralesional sites during human dermal leishmaniasis. PLoS Negl. Trop. Dis. 2010, 4(9):e819.
21. Seifert K. Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open Med. Chem. J. 2011, 5:31-39.
22. Seifert K., Escobar P., Croft S.L. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J. Antimicrob. Chemother. 2010, 65(3):508-511.
23. Sereno D., Cordeiro da Silva A., Mathieu-Daude F., Ouaissi A. Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol. Int. 2007, 56(1):3-7.
24. Siqueira-Neto J.L., Moon S., Jang J., Yang G., Lee C., Moon H.K., Genovesio A., Cechetto J., Freitas-Junior L.H. An image-based high content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. PLoS Negl. Trop. Dis. 2012, 6(6):e1671.
25. Sundarshan M., Weirather J.L., Wilson M.E., Sundar S. Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J. Antimicrob. Chemother. 2011, 66(8):1751-1755.
26. van der Meide W., Schoone G., Faber W., Zeegelaar J., De Vries H., Özbel Y., Lai A., Fat R., Leíla I., Coelho L., Kassi M., Schallig H. Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples. J. Clin. Microbiol. 2005, 43(11):5560-5566.
27. van der Meide W., Guerra J., Schoone G., Farenhorst M., Coelho L., Faber W., Peekel I., Schallig H. Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites. J. Clin. Microbiol. 2008, 46(1):73-78.